Hyperpolarized Pyruvate (13C) Injection for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Sunnybrook Health Sciences Centre, Toronto, CanadaBreast CancerNAC - Drug
Eligibility
18 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying a new MRI technique to see if it can detect early changes in breast cancer tumors during neoadjuvant chemotherapy.

Eligible Conditions
  • Breast Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 6 Months

6 Months
Accuracy of time resolved, 3D 13C pyruvate MR imaging using visual analysis of MRI images
Lactate Correlation using visual analysis of MRI Images
Time resolved, 3D 13C pyruvate MR images using MRI
Visual differentiation between tumour necrosis versus viable tumour

Trial Safety

Trial Design

2 Treatment Groups

Hyperpolarized Pyruvate (13C) Injection
1 of 2
Coil Testing
1 of 2

Active Control

Non-Treatment Group

13 Total Participants · 2 Treatment Groups

Primary Treatment: Hyperpolarized Pyruvate (13C) Injection · Has Placebo Group · Phase 1

Coil TestingPlaceboComparator Group · 2 Interventions: NAC, Coil Testing · Intervention Types: Drug, Other
Hyperpolarized Pyruvate (13C) InjectionActiveComparator Group · 2 Interventions: NAC, Hyperpolarized Pyruvate (13C) Injection · Intervention Types: Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
607 Previous Clinical Trials
1,468,162 Total Patients Enrolled
25 Trials studying Breast Cancer
12,713 Patients Enrolled for Breast Cancer
Charles Cunningham, PhDPrincipal InvestigatorSunnybrook Research Institute
5 Previous Clinical Trials
271 Total Patients Enrolled

Eligibility Criteria

Age 18 - 80 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How secure is the administration of Hyperpolarized Pyruvate (13C) Injection for those receiving treatment?

"Limited efficacy and safety data results in a score of 1 being assigned to Hyperpolarized Pyruvate (13C) Injection on our team's scale, considering it is still in Phase 1." - Anonymous Online Contributor

Unverified Answer

May I join this medical research initiative?

"People diagnosed with breast cancer and aged between 18 to 80 years of age are eligible for this research. Currently, the trial is looking to recruit 13 participants." - Anonymous Online Contributor

Unverified Answer

How many participants are being accepted into this research trial?

"Affirmative; the study's information on clinicaltrials.gov reveals that it is actively searching for participants. Inception occurred November 21st 2017 and was recently updated May 4th 2022, with a need of 13 enrollees from one medical facility." - Anonymous Online Contributor

Unverified Answer

Are applications currently being accepted for this research trial?

"Affirmative, clinicaltrials.gov data confirms that this research is presently recruiting participants. The trial was originally uploaded on November 21st 2017 and its details were last modified on May 4th 2022. Presently, 13 individuals are being sought from a single medical site." - Anonymous Online Contributor

Unverified Answer

Are geriatric individuals being admitted to this research project?

"This trial is only available for those aged 18 to 80. For minors, there are 74 clinical trials and 2505 opportunities for senior citizens aged 65 or above." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.